SciSparc & Clearmind Patent Targets Binge Disorders

Ticker: SPRC · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1611746

Scisparc Ltd. 6-K Filing Summary
FieldDetail
CompanyScisparc Ltd. (SPRC)
Form Type6-K
Filed DateOct 20, 2025
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: patent, collaboration, mental-health, r&d

TL;DR

SciSparc and Clearmind filed a patent for binge disorder treatments - big news for mental health tech!

AI Summary

On October 20, 2025, SciSparc Ltd. announced a collaboration with Clearmind that resulted in the publication of a U.S. patent application. This application targets binge behavior disorders, potentially impacting the development of new treatments.

Why It Matters

This patent application could lead to novel therapeutic approaches for binge behavior disorders, a significant area of unmet medical need.

Risk Assessment

Risk Level: medium — The filing is a patent application publication, which is a step in the development process and not a guarantee of a successful product or market impact.

Key Players & Entities

  • SciSparc Ltd. (company) — Registrant
  • Clearmind (company) — Collaborator
  • October 20, 2025 (date) — Date of press release
  • U.S. Patent Application (legal_document) — Subject of the filing

FAQ

What is the specific nature of the U.S. patent application filed by SciSparc and Clearmind?

The U.S. patent application targets binge behavior disorders.

What is the significance of this patent application for SciSparc Ltd.?

It represents a potential advancement in their therapeutic development pipeline for mental health conditions.

When was the press release announcing this patent application published?

The press release was published on October 20, 2025.

What is the relationship between SciSparc Ltd. and Clearmind in this context?

They are collaborators whose joint efforts led to the publication of the patent application.

Does this filing indicate that a product is already approved or available?

No, this filing is for a patent application publication, which is a step in the research and development process, not an approval or product launch.

Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2025-10-20 09:25:00

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: October 20, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.